naccord

As at the end of June 2024.

Key facts

Lead manager: Mark Piper Fund size: \$845m Ireland inception date: 26/09/2008 ISA/PEP eligible: Yes SIPP eligible: Yes UK reporting status: Yes FCA recognised: Yes CBol Authorised: Yes MAS restricted foreign scheme: Yes

International Peer Group: Morningstar EAA Fund USD Aggressive Allocation²

Other information Minimum investment

Initial (or currency equivalent): A class: \$5,000 T class: \$5,000 R class: \$50,000 H class \$5,000,000

Ongoing (or currency equivalent): \$1,000 Domicile: Dublin Custodian/Trustee: Northern Trust

Yield: 0.0%3 **SRRI:** 4⁴

Dealing

Cut-off time: 2pm Dealing frequency: Daily Contact Northern Trust (fax): +353 1 531 8516

Contact us

funds@canaccord.com UK: +44 20 7523 4552 Jersey: +44 1534 708 090 Guernsey: +44 1481 733 900 Isle of Man: +44 1624 690 100

Investment involves risk. The value of investments and the income from them can go down as well as up and you may not get back the amount originally invested.

Investors should carefully read the Key Investor Information Document (KIID) and Fund Supplement before making a decision to invest.

Past performance is not indicative of future performance.

The returns are shown in USD. These returns may differ significantly when converted to other currencies at the prevailing exchange rates.

This is a marketing communication and not a contractually binding document. Please refer to the prospectus of the UCITS and to the KIID. Do not base any final investment decision on this communication alone.

Investment objective The investment objective of the Fund is to generate capital growth by investing in an internationally diversified portfolio of shares and units in collective investment schemes and individual high quality fixed interest instruments

Return profile¹



Canaccord Genuity Opportunity Fund

* 2024 YTD is data for year to date from 01 January 2024 to 30 June 2024 Source: Morningstar & CGWM

Discrete performance (%)¹

Total return to end of last calendar quarter (peer group data from Morningstar, these figures are unaudited)

		01/07/2022 30/06/2023			01/07/2019 30/06/2020
Opportunity Fund	+15.93	+9.16	-18.34	+30.90	+1.13
Intl. peer group	+11.92	+8.12	-13.37	+26.60	-1.20

Cumulative performance (%)¹

Total return from inception to 30/06/2024 (peer group data from Morningstar, these figures are unaudited)

	1 month 3	months	YTD	1 year	3 years	5 years	(Apr 2001)
Opportunity Fund	+1.45	+1.35	+9.27	+15.93	+3.33	+36.79	+430.08
Intl. peer group	+1.46	+1.34	+6.58	+11.92	+4.82	+31.11	+141.55

Top 10 holdings (%)

iShares Core S&P 500 UCITS ETF	14.36
Vanguard S&P 500 UCITS ETF	6.32
Natixis Loomis Sayles US Growth Equity S1/A USD	4.91
Findlay Park American USD Inc	4.78
Natixis Harris Associates US Equity Q/A USD Acc	4.77
GQG Partners US Equity USD I Acc	4.76
Waverton European Capital Growth USD I Acc	4.46
Polar Capital North American I USD Inc	4.45
Pacific North of South EM All Cap Equity USD R2	4.02
Morant Wright Fuji Yield, IPY Acc	3.01

Morant Wright Fuji Yield JPY Acc

Source: CGWM

- 1. The performance data shown represents the actual performance of The Friends Provident International Limited Canaccord Genuity Opportunity Fund, which transferred into the Fund on 26/09/08 and was managed with comparable parameters and investment process by the same investment team as the Fund. The Fund commenced on 26/09/2008. Performance and expenses of the Fund will vary from this historical performance. Future asset allocation including geographical allocations will depend on prevailing market conditions and sentiment and may be significantly different to the asset allocation of the past. From 01/01/2019 the Fund performance shown has changed from the A class to the R class, for consistency with peers; performance and expenses of the Fund will vary from this point. Performance is shown against an international peer group for reference purposes only. 2. The International Peer Group was changed from GIFS USD Aggressive Allocation to EAA Fund USD Aggressive Allocation on 01/09/20 due
- to Morningstar ceasing to produce the GIFS. Past performance is not indicative of future performance

3. Source: Northern Trust.

4. The Synthetic Risk and Reward Indicator (SRRI) displays the historic volatility of the fund's performance and categorises it accordingly. The values will range from 1 to 7, where 1 will mean lower risk and 7 indicates that the level of risk is relatively high

Sector analysis (%)



Important information Please read over page

This document is for information purposes only and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Investments involve risk. The investments discussed in this document may not be suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment adviser. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor's base currency, the value of those investments, and any income from them, will be affected by movements in exchange rates. This effect could be unfavourable as well as favourable. Levels and bases for taxation may change.

Canaccord Genuity Investment Funds plc ("CGIF") is an umbrella fund with segregated liability between sub-funds. CGIF is incorporated with limited liability as an open-ended umbrella investment company with variable capital under the laws of Ireland with registered number 367917 and authorised under the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011. The registered office of CGIF is 3 Dublin Landings, North Wall Quay, Dublin 1, D01 C4E0. CGIF is regulated by the Central Bank of Ireland. CGIF is a recognised collective investment scheme for the purposes of Section 264 of the UK Financial Services and Markets Act, 2000. CGIF is classified as a Restricted Scheme by the Monetary Authority of Singapore under paragraph 2(3) of the Sixth Schedule to the Securities and Futures (Offers of Investments)(Collective Investment Schemes) Regulations 2009. CGIF is recognised in the Isle of Man under Paragraph 1 of Schedule 4 to the Collective Investment Schemes Act 2008. The Isle of Man Financial Services Authority does not vouch for the correctness of any statements or opinions expressed with regard to CGIF. In France, Germany and Italy a number of the CGIF sub-funds are registered under Article 93(3) of Directive 2009/65/EC of the European Union.

Canaccord Genuity Wealth Management ("CGWM") is a trading name of Canaccord Genuity Wealth (International) Limited ("CGWI") in Guernsey, Isle of Man and Jersey and of Canaccord Genuity Wealth Limited ("CGWL") which are subsidiaries of Canaccord Genuity Group Inc. For the UK: this document is issued by CGWL which is authorised and regulated by the Financial Conduct Authority. Registered Office: 88 Wood Street, London, EC2V 7QR. For Guernsey, Isle of Man and Jersey: this document is issued by CGWI which is licensed and regulated by the Guernsey Financial Services Commission, the Isle of Man Financial Services Authority and the Jersey Financial Services Commission and is a member of the London Stock Exchange. CGWI is registered in Guernsey. CGWI is registered under the Financial Services (Jersey) Law 1998 (as amended) to carry out "funds services business". The Jersey Financial Services Commission is protected by the Financial Services (Jersey) Law 1998, against any liability arising from the discharge of its functions under those laws. The information contained herein is based on materials and sources that we believe to be reliable, however, CGWM make no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. All opinions and estimates included in this document are subject to change without notice and CGWM are under no obligation to update the information contained herein. None of CGWM, their affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document. CGWM do not make any warranties, express or implied, that the products, securities or services advertised are available in your jurisdiction. Accordingly, if it is prohibited to advertise or make the products, securities or services available in your jurisdiction, or to you (by reason of nationality, residence or otherwise) such products, securities or services are not directed at you. CGWM and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In order to provide a comparison of the Fund's performance against that of its peers, the fund manager believes that the investment parameters of the Fund most closely match those of the international peer group. Investors should be aware however, that this fund may differ from those included in the international peer group in terms of fees, tax treatment or other features.

Canaccord Genuity Opportunity Fund – Manager's commentary

The Canaccord Genuity Opportunity Fund gained 1.45% in June, compared to a gain of 1.46% for its benchmark peer group, the Morningstar EAA Fund USD Aggressive Allocation sector. Over the last 12 months, the Fund has returned 15.93%, compared to a return of 11.92% for the peer group.

While the share price movements of Nvidia remained a major talking point during the month – more on that below - Europe and more specifically France managed to briefly take the top spot in the financial headlines, as French President Emmanuel Macron surprised everyone on the 9 June by calling snap parliamentary elections. His strategy appears to have backfired, however, as Marine Le Pen's radical right-wing National Rally party were victorious in the first round of parliamentary elections. French government bonds and equities were sold-off following Macron's announcement, as fears of a re-emergence of political radicalism gripped the marketplace. However, while French asset prices might remain volatile in the short-term as we await the final result, a full-blown financial crisis is unlikely no matter who garners power following the election. If France were ever to experience a 'Liz Truss' moment, the European Central Bank would act in a similar fashion as the Bank of England to clamp down on any risk that may threaten the integrity of investment markets and the euro.

Returning to Nvidia, the company briefly became the world's largest by market capitalisation during the month, surpassing Microsoft as it reached a market cap of \$3.326 trillion. However, that proved to be the catalyst for investors to take near-term profits and the company's stock price fell 12.89% over the next three trading sessions, allowing Microsoft to once again, reclaim the top spot. Nvidia still ended June up 12.69% and finished the first half of 2024 up a remarkable 149.50%.

In terms of activity, we trimmed the Fund's allocations to Europe - in part due to the political uncertainty in France - and Japan during the month, taking profits in the iShares Core EURO STOXX50 UCITS ETF, the Waverton European Capital Growth fund and the Morant Wright Fuji Yield fund. The proceeds were invested in the US, but not, as some might expect, in the mega-cap technology names that have driven the market higher for much of the past year. Instead, we added to the Fund's healthcare allocation, increasing the Fund's holding in the iShares S&P 500 US Health Care UCITS ETF. Much like the broader market, the healthcare sector is highly bifurcated. Excluding 'obesity pharma' which is an alternative mania candidate to the Magnificent 7 tech stocks, healthcare is a beaten-down sector that offers risk diversification at this juncture in the economic cycle. The sector also looks poised to benefit from an uptick in merger and acquisition activity, as cash-rich pharmaceutical companies look to boost their drug pipelines by taking advantage of the depressed valuations that many of their small to mid-cap biotechnology counterparts trade on.